Nebenwirkungen · Eptifibatide Accord
Eptifibatide Accord 0.75 mg/ml solution for infusion · Abschnitt 4.8 · PDF-Seite 7
HOS-135136 · Präparat HOS-097660
Administration of eptifibatide is associated with an increase in major and minor bleeding as classified by the criteria of the TIMI study group. At the recommended therapeutic dose, as administered in the PURSUIT trial involving nearly 11,000 patients, bleeding was the most common complication encountered during eptifibatide therapy. The most common bleeding complications were associated with cardiac invasive procedures (coronary artery bypass grafting (CABG)-related or at femoral artery access site).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-02T01:00:00Z · SHA-256 9396fc6df1ff96694d27eb7b74981a633ad8bf93b3393c54e43ba8b1ce931773 · Passage 61bf7230a4bc694094edf90f95c9eb97c3d5ebfe60df40ba006fea88b38bd2ac · Zeichen 3004–3510 im Abschnitt